Beijing InnoCare Pharma Tech Co., Ltd.
Beijing InnoCare Pharma Tech Co., Ltd.
Explore linked clinical trials.26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Prurigo Nodularis (PN) | Recruiting | Phase 2 | 2026-09-14 | NCT07236099 | |
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Not yet recruiting | Phase 3 | 2026-08-25 | NCT07784101 | |
| ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-18 | NCT06656494 | |
| A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Not yet recruiting | Phase 2 | 2026-07-27 | NCT07727486 | |
| A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2026-07-23 | NCT07082686 | |
| Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT07617493 | |
| Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects | Health Services Research | Recruiting | Phase 1 | 2026-06-18 | NCT07535099 | |
| Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous lupus erythematosus, skin disorder | Recruiting | Phase 2 | 2026-06-08 | NCT07440537 | |
| A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies | Part 1：r/r B-cell Malignancies; Part 2：B-cell Malignancies | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-08 | NCT04014205 | |
| Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 2 / Phase 3 | 2026-04-21 | NCT07378527 | |
| Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis Patients | Recruiting | Phase 3 | 2026-02-09 | NCT06842199 | |
| Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 2 | 2025-12-31 | NCT07251998 | |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 2 / Phase 3 | 2025-11-21 | NCT06378138 | |
| Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2025-09-15 | NCT06082102 | |
| Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors | Advanced Solid Tumors Harboring NTRK Fusion; Primary Central Nervous System Tumors Harboring NTRK Fusion | Recruiting | Phase 1 / Phase 2 | 2025-09-11 | NCT05745623 | |
| ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 3 | 2025-09-08 | NCT06775860 | |
| The Study of ICP-248 in Patients With Mature B-cell Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2025-09-08 | NCT05728658 | |
| A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-09-02 | NCT04685226 | |
| Evaluation of ICP-B794 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2025-08-22 | NCT07136558 | |
| ICP-332 in Subjects With Non-segmental Vitiligo | Non Segmental Vitiligo | Recruiting | Phase 2 / Phase 3 | 2025-08-07 | NCT07047612 | |
| Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2025-02-25 | NCT06845241 | |
| Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2024-12-27 | NCT05690581 | |
| Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Recruiting | Phase 3 | 2024-07-25 | NCT06521255 | |
| A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2024-02-07 | NCT05678270 | |
| Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | diffuse large B-cell lymphoma | Recruiting | Phase 2 | 2022-09-23 | NCT05552937 |